Given patients with substantial LVSI experience a pelvic recurrence rate of ~25%, how do you counsel patients with stage IA endometrioid endometrial cancer with LVSI regarding the relative risks/benefits of EBRT versus VBT alone?   

Please comment on toxicity profiles and the insufficient evidence regarding overall survival.



Answer from: Radiation Oncologist at Academic Institution

Answer from: at Academic Institution
Comments
Radiation Oncologist at McGill University Health Centre
Thank you very much for your thoughtful answer. Ma...
Radiation Oncologist at Vanderbilt-Ingram Cancer Center
While we know POLe mutated is a good prognostic fa...
Sign in or Register to read more

Answer from: Radiation Oncologist at Community Practice

Answer from: at Academic Institution

Answer from: at Community Practice